This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Austin, H A Articles by Illei, G G Search for Related Content PubMed PubMed Citation Articles by Austin, H A Articles by Illei, G G Social Bookmarking                         What's this?

Membranous lupus nephritis

National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, USA

G G Illei

National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, USA, illeig{at}mail.nih.gov

Membranous lupus nephritis (MLN) represents about 20% of clinically significant renal disease in lupus. Few studies have addressed directly the pathogenesis of MLN. Our assumptions about the underlying mechanisms are based on the combination of extrapolations from idiopathic membranous nephritis (mainly from animal models) and proliferative lupus nephritis. Natural history studies of MLN suggest a relatively low rate of progression to end-stage renal disease but a high rate of significant comorbidities. Historical changes in the criteria for pathologic diagnosis and classification of membranous lupus nephropathy have precluded definitive descriptions of the natural history, prognosis and treatment of this disorder. Patients with membranous lupus nephropathy should be treated early with angiotensin antagonists to minimize proteinuria, as well as lifestyle changes and appropriate drugs to reduce attendant cardiovascular risk factors. In patients with protracted nephrotic syndrome, consideration should be given to immunosuppressive therapies, including corticosteroids, cyclosporine, mycophenolate and cyclophosphamide. Prospective controlled trials are clearly needed in order to establish solid clinical practice guidelines for use of these drugs and other experimental therapies currently under study in membranous lupus nephropathy.

Key Words: classification • pathogenesis • prognosis • treatment

Lupus, Vol. 14, No. 1, 65-71 (2005)
DOI: 10.1191/0961203305lu2062oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. Melander, M. Sallee, P. Trolliet, S. Candon, X. Belenfant, E. Daugas, P. Remy, V. Zarrouk, E. Pillebout, C. Jacquot, et al. Rituximab in Severe Lupus Nephritis: Early B-Cell Depletion Affects Long-Term Renal Outcome Clin. J. Am. Soc. Nephrol., March 1, 2009; 4(3): 579 - 587. [Abstract] [Full Text] [PDF]

				C.-C. Szeto, B. C.-H. Kwan, F. M.-M. Lai, L.-S. Tam, E. K.-M. Li, K.-M. Chow, W. Gang, and P. K.-T. Li Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis Rheumatology, November 1, 2008; 47(11): 1678 - 1681. [Abstract] [Full Text] [PDF]

				H.O. Sun, W.X. Hu, H.L. Xie, H.T. Zhang, H.P. Chen, C.H. Zeng, Z.H. Liu, and L.S. Li Long-term outcome of Chinese patients with membranous lupus nephropathy Lupus, January 1, 2008; 17(1): 56 - 61. [Abstract] [PDF]

				A. Sinclair, G. Appel, M.A. Dooley, E. Ginzler, D. Isenberg, D. Jayne, D. Wofsy, and N. Solomons Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS) Lupus, December 1, 2007; 16(12): 972 - 980. [Abstract] [PDF]

				G. R. Bihl, M. Petri, and D. M. Fine Kidney biopsy in lupus nephritis: look before you leap Nephrol. Dial. Transplant., July 1, 2006; 21(7): 1749 - 1752. [Full Text] [PDF]